Dimerix Limited (ASX:DXB) Insider Buys A$66,880.80 in Stock

Dimerix Limited (ASX:DXB) insider Sonia Poli acquired 167,202 shares of Dimerix stock in a transaction on Thursday, July 25th. The shares were purchased at an average price of A$0.40 ($0.26) per share, for a total transaction of A$66,880.80 ($43,712.94).

Dimerix Price Performance

The company has a current ratio of 4.84, a quick ratio of 7.91 and a debt-to-equity ratio of 83.19.

Dimerix Company Profile

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology.